Comments on "dynamic ¹⁸ F-FDG PET/CT can predict the major pathological response to neoadjuvant immunotherapy in non-small cell lung cancer"

Thorac Cancer. 2022 Dec;13(24):3513-3514. doi: 10.1111/1759-7714.14710. Epub 2022 Oct 26.

Authors

Shan-Ying Wang^{1

2}, Yu-Chien Shiau¹, Chen-Xiong Hsu^{2

3}

Affiliations

¹ Department of Nuclear Medicine, Far Eastern Memorial Hospital, New Taipei City, Taiwan.
² Department of Biomedical Imaging and Radiological Sciences, National Yang Ming Chiao Tung University, Taipei, Taiwan.
³ Division of Radiation Oncology, Department of Radiology, Far Eastern Memorial Hospital, New Taipei City, Taiwan.

No abstract available

Keywords: 18F-FDG PET/CT; SUV; metabolic tumor volume; total lesion glycolysis; volume-based metabolic parameters.

Publication types

Letter
Comment

MeSH terms

Carcinoma, Non-Small-Cell Lung* / diagnostic imaging
Carcinoma, Non-Small-Cell Lung* / drug therapy
Fluorodeoxyglucose F18 / therapeutic use
Humans
Immunotherapy
Lung Neoplasms* / diagnostic imaging
Lung Neoplasms* / drug therapy
Neoadjuvant Therapy
Positron Emission Tomography Computed Tomography
Prognosis
Retrospective Studies
Tumor Burden

Substances

Fluorodeoxyglucose F18